Search Clinical Trials
 
By Condition
 
By Location (USA)
 
By Location (Other)
 
By Sponsor
 
Resources
 
Privacy Policy
 
About Us
Disclaimer
A Study of 1592U89 in HIV-Infected Children Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about A Study of 1592U89 in HIV-Infected Children conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. A Study of 1592U89 in HIV-Infected Children Clinical research trials and A Study of 1592U89 in HIV-Infected Children medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as A Study of 1592U89 in HIV-Infected Children. A Study of 1592U89 in HIV-Infected Children Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a A Study of 1592U89 in HIV-Infected Children clinical trial. Subjects often receive the most expert healthcare possible for their A Study of 1592U89 in HIV-Infected Children condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.

Home > "A" Clinical Trials Conditions > A Study of 1592U89 in HIV-Infected Children

A Study of 1592U89 in HIV-Infected Children



A Study of 1592U89 in HIV-Infected Children

For Condition: HIV Infections
Status: Completed
Sponsor(s): Glaxo Wellcome ,
Synopsis: The purpose of this study is to see if it is safe to give 1592U89 to children (aged 6 months until 14th birthday) with advanced HIV infection who have few treatment options available. The study also examines the effect 1592U89 has on the levels of HIV in the blood.
Details: This is an open-label, non-randomized study. All patients will be treated with 1592U89. Additionally, since optimal therapy usually includes the combined use of 2 or more antiretroviral agents in advanced patients, other novel antiretroviral therapies may be accessed through commercial means or via compassionate use programs. NOTE: 1592U89 should not be administered as a single new agent added to a failing treatment regimen.
Eligibility:
Study Type:  Interventional, Treatment, Open Label, Safety Study
Minimum Age/Maximum Age: 6 Months/13 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Intravenous immunoglobulin G. - Erythropoietin, granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor, for the management of hematologic toxicity. Patients must have: - Documented HIV infection. - High risk for disease progression or mortality as defined by either of the following: - Viral load > 100,000 copies/ml and CD4 cells < 15% of total lymphocyte count despite at least 4 weeks of therapy with commercially available antiretrovirals or as a result of no therapy due to treatment-limiting toxicity of ZDV, 3TC, and ddI; or HIV-associated encephalopathy refractory to ZDV-containing regimen. - No access to any 1592U89 pediatric study where the patient could qualify for inclusion. - Parent or legal guardian with the ability to understand and provide written consent for the patient to participate in the trial. Study patients over 13 years should also give written informed consent whenever possible. Exclusion Criteria Co-existing Condition: Patients with any of the following symptoms or conditions are excluded: - In the investigator's opinion, the patient is unlikely to comply with the requirements of the study. - Renal failure requiring dialysis. - Hepatic failure evident by Grade 3 or 4 hyperbilirubinemia and AST > 10 X upper limits of normal. - Life-threatening infection or other chronic disease that may interfere with taking 1592U89 or compromise the patient's safety. Patients with the following prior conditions are excluded: Documented hypersensitivity to 1592U89 or any other nucleoside analogue. See Inclusion - General Criteria.
Total Enrollment: 250

Location and Contact Information:

Glaxo Wellcome Inc
Research Triangle Park,  North Carolina,  277093398
United States
 


Additional Information:
Study ID Numbers:  238E;  CNAA3007
Study Start Date: 
Record last reviewed: December 1998
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00002197

Other Hiv Infections Studies:
1. The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success with Protease Inhibitors

2. Follow-up Protocol for Patients with Cancer/AIDS/Skin Disease

3. Valganciclovir Prevention of Cytomegalovirus (CMV) Organ Damage

4. Problems Associated with the Use of Anti-HIV Drugs in HIV-Infected Pregnant Women

5. Effects of Therapeutic HIV Vaccination on Control of HIV after Discontinuation of Anti-HIV Drugs

Related Studies:

Other HIV Infections Clinical Trials
Other North Carolina Clinical Trials
Other Research Triangle Park Clinical Trials

A Study of 1592U89 in HIV-Infected Children
Modify your Search

  Other HIV Infections Clinical Trials
  Other North Carolina Clinical Trials
  Other Research Triangle Park Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103